5,7-dimethoxycoumarin profile

5,7-Dimethoxycoumarin is a naturally occurring coumarin derivative found in various plants. It has been synthesized through various methods, including the Pechmann condensation of resorcinol with ethyl acetoacetate. 5,7-Dimethoxycoumarin exhibits diverse biological activities, including antioxidant, antimicrobial, and anti-inflammatory properties. It has been shown to inhibit the growth of various bacteria and fungi. The compound also possesses anti-cancer potential, specifically against certain leukemia cell lines. Its importance stems from its potential as a lead compound for developing new pharmaceuticals. Research focuses on understanding its mechanism of action, optimizing its synthesis, and evaluating its therapeutic potential in various disease models.'

5,7-dimethoxycoumarin: has photobiological activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2775
CHEMBL ID	481049
CHEBI ID	113528
SCHEMBL ID	516577
MeSH ID	M0113338

Synonym
5,7-dimethoxy-chromen-2-one
AC-20780
BRD-K78612426-001-02-6
2h-1-benzopyran-2-one, 5,7-dimethoxy-
coumarin, 5,7-dimethoxy-
nsc217987
nsc-217987
KBIO1_000391
DIVK1C_000391
SDCCGMLS-0066597.P001
brn 0187066
5,7-dimethoxy-2-benzopyrone
einecs 207-646-4
ai3-36094
ccris 3595
nsc 102793
SPECTRUM_000243
BSPBIO_003016
SPECTRUM5_001348
NCGC00178344-01
5,7-dimethoxychromen-2-one
5,7-dimethoxy-coumarin
IDI1_000391
limetin
citropten
5,7-dimethoxycoumarin
citroptene
487-06-9
nsc-102793
mls002703744 ,
citraptene
limettin
2h-1-benzopyran-2-one,7-dimethoxy-
nsc102793
coumarin,7-dimethoxy-
5,7-dimethoxycoumarin, 98%
NCGC00094841-01
NCGC00094841-02
KBIO2_000723
KBIOGR_001222
KBIOSS_000723
KBIO2_003291
KBIO3_002236
KBIO2_005859
SPECTRUM3_001398
SPBIO_000707
NINDS_000391
SPECTRUM2_000814
SPECTRUM4_000781
SPECTRUM1500707
MLS002472928
smr000112321
CHEBI:113528
MLS002207304
HMS501D13
inchi=1/c11h10o4/c1-13-7-5-9(14-2)8-3-4-11(12)15-10(8)6-7/h3-6h,1-2h3
nxjcrelrqhzbqa-uhfffaoysa-
HMS1921E18
CHEMBL481049
AQ-358/43417403
5,7-dimethoxy-2h-chromen-2-one
NCGC00094841-04
NCGC00094841-03
dtxcid9021421
dtxsid1041421 ,
tox21_300942
NCGC00254844-01
cas-487-06-9
5,7-dimethoxychromen-2-one;citropten
A827593
HMS2268I06
CCG-40277
bdbm93217
coumarin derivative, 2a
5-18-03-00199 (beilstein handbook reference)
jwe1qq247n ,
unii-jwe1qq247n
FT-0619848
S11976
AKOS015915990
S5143
limettin [mi]
dimethoxycoumarin, 5,7-
5,7-dimethoxy-2h-1-benzopyran-2-one
SCHEMBL516577
5,7-dimethyloxy-2h-1-benzopyran-2-one
NXJCRELRQHZBQA-UHFFFAOYSA-N
5,7-dimethoxy-2h-1-benzo-pyran-2-one
AC-34193
5, 7-dimethoxycoumarin
mfcd00006870
citropten, analytical standard
SR-05000002446-1
sr-05000002446
AS-63137
Q3599218
HY-N7085
10.14272/NXJCRELRQHZBQA-UHFFFAOYSA-N.1
doi:10.14272/nxjcrelrqhzbqa-uhfffaoysa-n.1
AMY10289
BRD-K78612426-001-05-9
STL193281
5,7-dimethoxycoumarin;limettin
CS-W015331
EN300-9540141

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	25.1189	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	25.1189	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	3.1623	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	35.4813	5.6234	17.2929	31.6228	AID485281
Chain A, Cruzipain	Trypanosoma cruzi	Potency	31.6228	0.0020	14.6779	39.8107	AID1476
acid sphingomyelinase	Homo sapiens (human)	Potency	25.1189	14.1254	24.0613	39.8107	AID504937
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	22.9833	0.1000	20.8793	79.4328	AID588453; AID588456
ATAD5 protein, partial	Homo sapiens (human)	Potency	20.5878	0.0041	10.8903	31.5287	AID504467
GLI family zinc finger 3	Homo sapiens (human)	Potency	15.3553	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	29.3639	0.0002	21.2231	8,912.5098	AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	28.1838	0.0112	12.4002	100.0000	AID1030
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	21.8684	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	68.5896	0.0004	17.9460	75.1148	AID1346795
glucocerebrosidase	Homo sapiens (human)	Potency	28.1838	0.0126	8.1569	44.6684	AID2101
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	54.9410	0.0010	24.5048	61.6448	AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	48.9662	0.0010	19.4141	70.9645	AID743191
alpha-galactosidase	Homo sapiens (human)	Potency	22.8741	4.4668	18.3916	35.4813	AID1467; AID2107
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	30.6379	0.0017	23.8393	78.1014	AID743083
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	113.0040	0.0391	47.5451	146.8240	AID1224845
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	15.8489	0.0018	15.6638	39.8107	AID894
lethal(3)malignant brain tumor-like protein 1 isoform I	Homo sapiens (human)	Potency	0.0398	0.0752	15.2253	39.8107	AID485360
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	31.6228	0.0316	10.2792	39.8107	AID884; AID885
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	28.1838	0.2512	15.8432	39.8107	AID504327
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	1.1463	10.0000	AID1902934
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP catabolic process	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of heart rate	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of type II interferon production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-2 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
positive regulation of interleukin-5 production	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of peptidyl-serine phosphorylation	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of heart contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
T cell receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
establishment of endothelial barrier	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
adrenergic receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cardiac muscle cell contraction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conduction	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
negative regulation of relaxation of cardiac muscle	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP-mediated signaling	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
3',5'-cyclic-nucleotide phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
enzyme binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
signaling receptor regulator activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cAMP binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
beta-2 adrenergic receptor binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
transmembrane transporter binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
metal ion binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
ATPase binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
scaffold protein binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
heterocyclic compound binding	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
centrosome	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
apical plasma membrane	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
voltage-gated calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
calcium channel complex	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
cytosol	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
nucleus	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay ID	Title	Year	Journal	Article
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1902934	Inhibition of PDE4D2 (86 to 413 residues) (unknown origin) expressed in Escherichia coli BL21 using [3H-GMP] or [3H-AMP] as substrate incubated for 15 mins by liquid scintillation counting method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
AID377034	Antimicrobial activity against Proteus mirabilis after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID377030	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID377035	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID377031	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID344670	Nematicidal activity against Bursaphelenchus xylophilus measured per cotton ball after 4 days by serial dilution method	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Synthesis and biological evaluation of alkoxycoumarins as novel nematicidal constituents.
AID377029	Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID377033	Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID377032	Antimicrobial activity against Enterobacter cloacae ATCC 13047 after 24 hrs by disk diffusion assay	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1799899	NS5B Inhibition Assay from Article 10.1111/cbdd.12105: \\Evaluation of Coumarin and Neoflavone Derivatives as HCV NS5B Polymerase Inhibitors.\\	2013	Chemical biology & drug design, May, Volume: 81, Issue:5	Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (9.52)	18.7374
1990's	4 (9.52)	18.2507
2000's	10 (23.81)	29.6817
2010's	19 (45.24)	24.3611
2020's	5 (11.90)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.27%)	6.00%
Case Studies	1 (2.27%)	4.05%
Observational	0 (0.00%)	0.25%
Other	42 (95.45%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
coumarin 2H-chromen-2-one: coumarin derivative	7.69	3	coumarins	fluorescent dye; human metabolite; plant metabolite
5-methoxypsoralen 5-Methoxypsoralen: A linear furanocoumarin that has phototoxic and anti-inflammatory properties, with effects similar to METHOXSALEN. It is used in PUVA THERAPY for the treatment of PSORIASIS.. 5-methoxypsoralen : A 5-methoxyfurocoumarin that is psoralen substituted by a methoxy group at position 5.	3.1	5	5-methoxyfurocoumarin; organic heterotricyclic compound; psoralens	hepatoprotective agent; plant metabolite
caffeine [no description available]	1.98	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	7.07	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
methacrylic acid methacrylic acid: RN given refers to parent cpd. methacrylic acid : An alpha,beta-unsaturated monocarboxylic acid that is acrylic acid in which the hydrogen at position 2 is substituted by a methyl group.	2.1	1	alpha,beta-unsaturated monocarboxylic acid
methoxsalen Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.	3.38	7	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
pimpinellin pimpinellin: from Heracleum laciniatum; cause of phototoxicity in patient with vitiligo	6.96	1	furanocoumarin
ficusin Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.	1.96	1	psoralens	plant metabolite
ethylene dimethacrylate ethylene glycol dimethacrylate : The enoate ester that is the 1,2-bis(methacryloyl) derivative of ethylene glycol.	2.1	1	enoate ester	allergen; cross-linking reagent; polymerisation monomer
thiazoles [no description available]	2.04	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
angelicin angelicin: used as tranquillizer; sedative; or anticonvulsant; structure	2.05	1	furanocoumarin
herniarin herniarin: methoxy analog of umbelliferone; structure. herniarin : A member of the class of coumarins that is coumarin substituted by a methoxy group at position 7.	2.04	1	coumarins	fluorochrome
trimethylolpropane trimethacrylate trimethylolpropane trimethacrylate: acrylate derivative found in ultraviolet curing inks; structure in 1st source	2.1	1	carbonyl compound
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.02	1	penicillin allergen; penicillin	antibacterial drug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	6.97	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
3-carbethoxypsoralen [no description available]	1.96	1	ethyl ester; psoralens
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.04	1	organic bromide salt	colorimetric reagent; dye
xanthyletine xanthyletine: structure	2.02	1	coumarins
isopimpinellin isopimpinellin: from Ruta graveolens & Heracleum lanatum; structure	7.71	3	psoralens
seselin seselin: structure in first source	2.02	1	coumarins	metabolite
5-hydroxymethylfurfural 5-hydroxymethylfurfural: has antisickling activity; HMF is the causative component in honey that affects the presystemic metabolism and pharmacokinetics of GZ in-vivo. 5-hydroxymethylfurfural : A member of the class of furans that is furan which is substituted at positions 2 and 5 by formyl and hydroxymethyl substituents, respectively. Virtually absent from fresh foods, it is naturally generated in sugar-containing foods during storage, and especially by drying or cooking. It is the causative component in honey that affects the presystemic metabolism and pharmacokinetics of GZ in-vivo.	2.05	1	arenecarbaldehyde; furans; primary alcohol	indicator; Maillard reaction product
5,7-dimethoxy-4-methyl-1-benzopyran-2-one [no description available]	2.08	1	coumarins
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	2.02	1
roflumilast [no description available]	2.41	1	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
2-hydroxycinnamic acid trans-2-coumaric acid : The trans-isomer of 2-coumaric acid.. 2-coumaric acid : A monohydroxycinnamic acid in which the hydroxy substituent is located at C-2 of the phenyl ring.	2.04	1	2-coumaric acid; phenols	antioxidant; metabolite
sesquiterpenes [no description available]	2.21	1
nootkatone nootkatone: RN given refers to cpd without isomeric designation; structure given in first source. (+)-nootkatone : A sesquiterpenoid that is 4,4a,5,6,7,8-hexahydronaphthalen-2(3H)-one which is substituted by methyl groups at positions 4 and 4a, and by an isopropenyl group at position 6 (the 4R,4aS,6R stereoisomer).	2.21	1	carbobicyclic compound; enone; sesquiterpenoid	fragrance; insect repellent; plant metabolite
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.05	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
hymecromone Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.	2.08	1	hydroxycoumarin	antineoplastic agent; hyaluronic acid synthesis inhibitor
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	2.02	1	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
7-hydroxycoumarin 7-oxycoumarin: derivatives have anti-oxidant properties. umbelliferone : A hydroxycoumarin that is coumarin substituted by a hydroxy group ay position 7.	2.08	1	hydroxycoumarin	fluorescent probe; food component; plant metabolite
wedelolactone wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.	2.08	1	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
calcipotriene [no description available]	2.41	1	cyclopropanes; hydroxy seco-steroid; seco-cholestane; secondary alcohol; triol	antipsoriatic; drug allergen
5,7-dihydroxy-4-methylcoumarin [no description available]	2.08	1	hydroxycoumarin
serratin serratin: isolated from the essential oil of Clerodendron serratum; structure in first source	2.08	1	neoflavonoid
bergamottin bergamottin: constituent of bergamot oil; structure given in first source	2.01	1	furanocoumarin	metabolite
5-geranyloxy-7-methoxycoumarin 5-geranyloxy-7-methoxycoumarin: structure in first source	2.08	1	terpene lactone
beta-elemene beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface. beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.. (-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.	2.21	1	beta-elemene	antineoplastic agent
valencene valencene: structure in first source. (+)-valencene : A carbobicyclic compound and sesquiterpene that is 1,2,3,4,4a,5,6,7-octahydronaphthalene which is substituted a prop-1-en-2-yl group at position 3 and by methyl groups at positions 4a and 5 (the 3R,4aS,5R- diastereoisomer).	2.21	1	carbobicyclic compound; polycyclic olefin; sesquiterpene
an2728 crisaborole: NSAID, Dermatologic Agent; structure in first source. crisaborole : A member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults.	2.41	1	aromatic ether; benzoxaborole; nitrile	antipsoriatic; non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	4.62	26	benzenes; hydroxycoumarin; methyl ketone
trypan blue Trypan Blue: A diazo-naphthalene sulfonate that is widely used as a stain.. trypan blue : An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid).	2.04	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.54	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.54	2
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Benign Neoplasms [description not available]	3.03	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.03	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Palmoplantaris Pustulosis [description not available]	2.41	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	2.41	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.9	2
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.9	2
Bowel Diseases, Inflammatory [description not available]	2.6	1
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	2.6	1
Dermatitis, Contact, Phototoxic [description not available]	2.1	1
Malignant Melanoma [description not available]	3.16	5
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	3.16	5
Melanoma, Amelanotic An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)	2.05	1
Cancer of Colon [description not available]	2.08	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.08	1
Disease Exacerbation [description not available]	2.04	1
B16 Melanoma [description not available]	2.04	1
Fasciculation Involuntary contraction of the muscle fibers innervated by a motor unit. Fasciculations may be visualized as a muscle twitch or dimpling under the skin, but usually do not generate sufficient force to move a limb. They may represent a benign condition or occur as a manifestation of MOTOR NEURON DISEASE or PERIPHERAL NERVOUS SYSTEM DISEASES. (Adams et al., Principles of Neurology, 6th ed, p1294)	2.01	1
Cramp [description not available]	2.01	1
Day Blindness [description not available]	2.01	1
Muscle Cramp A sustained and usually painful contraction of muscle fibers. This may occur as an isolated phenomenon or as a manifestation of an underlying disease process (e.g., UREMIA; HYPOTHYROIDISM; MOTOR NEURON DISEASE; etc.). (From Adams et al., Principles of Neurology, 6th ed, p1398)	2.01	1
Bleb [description not available]	2.38	2
Actinic Reticuloid Syndrome [description not available]	1.96	1

5,7-dimethoxycoumarin

Description

Cross-References

Synonyms (105)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (41)

Potency Measurements

Inhibition Measurements

Biological Processes (18)

Molecular Functions (14)

Ceullar Components (8)

Bioassays (34)

Research

Studies (42)

Market Indicators

Research Demand Index: 21.72

Study Types

5,7-dimethoxycoumarin

Description

Cross-References

Synonyms (105)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (41)

Potency Measurements

Inhibition Measurements

Biological Processes (18)

Molecular Functions (14)

Ceullar Components (8)

Bioassays (34)

Research

Studies (42)

Market Indicators

Research Demand Index: 21.72

Study Types

Related Drugs (42)

Related Conditions (28)